View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. Theme
  2. Macro
  3. Covid-19
May 12, 2020

How BerGenBio became a frontrunner in UK hunt for Covid-19 treatment

By Jamie Bell

Firms across the healthcare sector are working day and night to develop the first approved treatment for patients with Covid-19 — and, in the UK, BerGenBio looks to be a leading name in this particular race.

 At the end of April, the Norwegian biotech company had its daily oral drug bemcentinib fast-tracked towards Phase II clinical trials by the government-funded ACCORD (Accelerating Covid-19 Research & Development platform) study.

 We take a closer look at the work BerGenBio has done to become one of the firms at the forefront of the UK’s hunt for an effective virus treatment.

Read the full article here.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy


Thank you for subscribing to Clinical Trials Arena